ESR1 and breast cancer: Ultimately, this knowledge suggests that targeting Annexin A2 merits investigation as a novel therapeutic strategy in treating the pharmacologically challenging ER negative subtype, and this may help prevent breast cancer progression to the later metastatic stages of disease.